Madison, WI – According to filings with the U.S. Securities and Exchange Commission, BrainXell is raising $13,249,812.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Shouming Du played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BrainXell
BrainXell focuses on neural cells for therapeutic development. Founded in 2015 by Prof. Su-Chun Zhang with help from the Discovery to Product (D2P) program of University of Wisconsin Madison, it is based on the proprietary technology of directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neurons. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells and provides large-scale production of highly enriched, functionally specialized neural cells to the pharmaceutical and biotechnology industry. BrainXell also aims to develop stem cell therapy for neurological injuries and diseases through collaboration with pharmaceutical and healthcare industry. BrainXells mission is to make our brain healthy and well.

To learn more about BrainXell, visit http://brainxell.com/

Contact:
Shouming Du, Chief Executive Officer
608-220-3240
https://www.linkedin.com/in/shoumingdu/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved